Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8636926 | 0.90 | NPC1 (0.70) | NPC1RAB9AHPGDALDH1A1MAPT | |
| SCHEMBL17241597 | 0.88 | MAPT (0.72) | NPC1RAB9AHPGDALDH1A1KDM4E | |
| SCHEMBL31267447 | 0.86 | ALDH1A1 (0.68) | HPGDALDH1A1KDM4ELMNAHSD17B10 | |
| SCHEMBL10675512 | 0.84 | SMN1; SMN2 (0.59) | NPC1RAB9AHPGDALDH1A1LMNA | |
| SCHEMBL11880873 | 0.84 | CA1 (0.74) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL27592472 | 0.83 | NPC1 (0.67) | NPC1RAB9AHPGDALDH1A1MAPT | |
| SCHEMBL2236766 | 0.83 | HPGD (0.77) | HPGDALDH1A1KDM4ELMNAHSD17B10 | |
| SCHEMBL1849467 | 0.83 | MAPT (0.79) | NPC1RAB9AHPGDALDH1A1KDM4E | |
| SCHEMBL866062 | 0.82 | ALDH1A1 (0.64) | HPGDALDH1A1KDM4ELMNAHSD17B10 | |
| SCHEMBL17833343 | 0.82 | IKBKB (0.55) | NPC1RAB9AHPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117137048-A | Flavor composition, food comprising the same, and method for increasing the flavor intensity of the umami taste of food | 马斯公司 | 2023-12-01 | — | — | CN | claimed |
| CN-105198786-A | Aryl-substituted amide compound, preparing method thereof, medicine composition comprising same, and application thereof | INST MED BIOTECHNOLOGY CAMS | 2015-12-30 | — | — | CN | claimed |
| US-12440484-B2 | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2025-10-14 | — | — | US | disclosed |
| EP-4403042-A2 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117137048-A | Flavor composition, food comprising the same, and method for increasing the flavor intensity of the umami taste of food | 马斯公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4216958-A2 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230079386-A1 | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2023-03-16 | — | — | US | disclosed |
| EP-3976602-A1 | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022067100-A2 | PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-31 | — | — | WO | disclosed |
| CN-105198786-A | Aryl-substituted amide compound, preparing method thereof, medicine composition comprising same, and application thereof | INST MED BIOTECHNOLOGY CAMS | 2015-12-30 | — | — | CN | disclosed |
| US-20140024749-A1 | Polymer and Compositions Thereof | LUBRIZOL ADVANCED MATERIALS, INC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024749-A1 | Polymer and Compositions Thereof | LUBRIZOL ADVANCED MATERIALS, INC (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2007084162-A2 | SIRTUIN INHIBITING COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1558260-A4 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | NPS PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| CN-1708306-A | Quinazolinone compounds as calcilytics | NPS PHARMA INC (US) | 2005-12-14 | — | — | CN | disclosed |
| EP-1558260-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041755-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079386-A1 | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC11, HDAC3 | NPC1 4445/4885RAB9A 3654/4885HPGD 1629/4885 |
| US-12440484-B2 | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC1, HDAC11, HDAC3 | NPC1 4445/4885RAB9A 3654/4885HPGD 1629/4885 |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | CALCR, CALCRL, CASR | NPC1 2093/4885RAB9A 444/4885HPGD 1791/4885 |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | NPC1 3211/4885RAB9A 2849/4885HPGD 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.